Biomimetic hydroxyapatite as potential polymeric nanocarrier for the treatment of rheumatoid arthritis

Journal of Biomedical Materials Research. Part a
Quratul AinHussain Ali

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune disease of unknown etiology with much higher prevalence in world's population. RA is initially associated with inflammation of joints and cartilages that ultimately leads to their destruction thus requiring a therapeutic intervention. The available conventional therapeutic strategies for RA are not satisfactory because of the associated side effects such as toxicity, delayed action, and dependence. Therefore, a carrier system is required that should deliver the drug to the target site with minimal side effects. In this connection, nanocarrier systems are of prime importance because of the associated benefits such as their nano-scaled size, targeted drug delivery, and reduced toxicity that can improve the patient's compliance. Moreover, in the past few decades, nano-particulate-based drug delivery approaches that have been investigated for the treatment of RA include ceramics, polymers, and hydrogels. Among these nanocarrier systems, ceramics like hydroxyapatite have gathered striking attention due to their bioactive, biocompatible, and bio-conductive characteristics. Nano-sized hydroxyapatite (HA) permeates the bone tissues and serves as a source of calcium phosphates required f...Continue Reading

References

Feb 13, 2001·Journal of Controlled Release : Official Journal of the Controlled Release Society·K S SoppimathW E Rudzinski
Feb 24, 2001·Critical Reviews in Biomedical Engineering·J L Ong, D C Chan
Dec 5, 2006·Current Opinion in Rheumatology·Lars KlareskogLars Alfredsson
May 26, 2007·Nature Reviews. Immunology·Iain B McInnes, Georg Schett
Jun 13, 2009·Arthritis Research & Therapy·Sherine E Gabriel, Kaleb Michaud
Mar 2, 2010·Arthritis and Rheumatism·Ted R Mikuls
Dec 24, 2010·Hand Clinics·J Michelle Kahlenberg, David A Fox
Dec 14, 2011·The New England Journal of Medicine·Iain B McInnes, Georg Schett
May 15, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Bernard C M te BoekhorstKlaas Nicolay
Feb 20, 2014·Annals of the Rheumatic Diseases·Marita CrossLyn March
Sep 27, 2014·International Journal of Nanomedicine·Volkmar WeissigNicole Murdock
Jun 19, 2015·Nanomedicine·Leena Kumari PrasadZhengrong Cui
May 18, 2016·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Samira JafariKhosro Adibkia
Dec 14, 2016·The New England Journal of Medicine·Steven E NissenUNKNOWN PRECISION Trial Investigators
Mar 8, 2017·Langmuir : the ACS Journal of Surfaces and Colloids·Yulia RyabenkovaAnant Paradkar
May 17, 2017·Australian Prescriber·Tom D Wilsdon, Catherine L Hill
May 17, 2017·Australian Prescriber·Megan Purvey, George Allen

❮ Previous
Next ❯

Citations

Jun 2, 2020·Drug Development and Industrial Pharmacy·Behrad GhiasiVuk Uskoković
Oct 6, 2020·Evidence-based Complementary and Alternative Medicine : ECAM·Zeyun YuPing Wu
Jan 10, 2021·Pharmaceutics·Daniela Placha, Josef Jampilek
Jan 11, 2021·International Journal of Biological Macromolecules·Shweta PandeySushama Talegaonkar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.